Main Conference: 28-30 April 2026 | Vienna, Austria
Downstream Processing
Purifying novel molecules with continuous processes and next-gen membrane tech.
Go Beyond Theory in Purification & Recovery
The Downstream Processing track is a 3-day deep dive into de-bottlenecking your purification train. This track is packed with case studies on adopting continuous processes , implementing novel technologies like membranes and magnetic beads , and developing robust purification strategies for complex, non-platform molecules. Hear from global experts on how to build a sustainable, efficient, and intensified downstream factory..
Session Spotlight: Downstream Processing
Beyond Protein A: Building a Non-Affinity Purification Toolbox for the Post-mAb Era
Wednesday 29th April 2026 11:20am
Johannes Buyel, Head of Department at BOKU
- Adapting purification platforms for the industry movement beyond antibodies
- Developing robust non-affinity chromatography steps:
- E.g. IEX, HIC, MMC for Novel Proteins lacking Fc region
- Roadmap for purifying the next generation of therapeutics
Track Themes: A Blueprint for Downstream De-Bottlenecking
Master Next-Gen Purification
Get proven strategies for purifying complex, non-platform molecules, from viral gene therapy vectors and plasmids to emerging modalities like exosomes and mRNA.
Go Beyond the Column
Explore the rise of novel purification tools. See case studies on membrane adsorbers , magnetic beads , and join the debate on 'Resins vs. Membranes'.
Implement Continuous & Intensified Processes
Get the business case for process intensification and see how leaders are integrating end-to-end continuous purification platforms guided by digital twins.
Build the Sustainable Factory
Learn practical strategies for automating buffer preparation and implementing green chemistry principles to reduce your environmental footprint and COGS.
Actionable Insights from our Downstream Processing Experts
Explore the full Downstream Processing Agenda
Downstream Processing: Q&A & Expert Insights
What are the purification challenges for viral gene therapy vectors?
Unlike monoclonal antibodies, viral vectors (like AAV) lack a standard Protein A platform. Downstream processing must be tailored to separate empty from full capsids and remove specific impurities. Developing a "platform" approach for these vectors involves optimising chromatography steps to handle the unique properties of different serotypes while maintaining high yield.
How is the industry moving "Beyond Protein A" for novel proteins?
For therapeutic proteins that lack an Fc region, manufacturers are building a non-affinity purification toolbox. This involves developing robust steps using Ion Exchange (IEX), Hydrophobic Interaction (HIC), and Mixed-Mode Chromatography (MMC) to ensure high purity and HCP clearance without relying on expensive affinity resins.
Can magnetic beads replace chromatography in bioprocessing?
Magnetic bead technology offers a scalable, column-free alternative for separation, particularly for cell-based therapeutics and viral vectors. This method provides "gentle" processing with low shear stress, which is vital for maintaining cell viability and achieving high-purity separations without the pressure limitations of traditional columns
How does "Green Chemistry" impact downstream buffer management?
To improve sustainability, DSP operations are shifting towards bio-based raw materials and green solvents for buffer preparation. This strategy aims to reduce the carbon footprint of chromatography operations and hazardous waste disposal, balancing environmental goals with economic and operational efficiency.